In conclusion, these studies have emphasized the CD8+ T cell promoting tumor cell ferroptosis, suggesting that targeting the Xc-/GSH/GPX4 pathway in combination with anti-PD-1/PD-L1 antibody may be an effective tumor immunotherapy combination strategy. Here, GPX4 is linked to neoplasm.